Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03550833
Other study ID # CHUBX 2018/01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 13, 2018
Est. completion date July 4, 2019

Study information

Verified date September 2019
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rheumatoid Arthritis (RA) is an inflammatory rheumatic disease that can lead to structural damage and handicap. The RA physiopathology is multifactorial, including genetic and environmental risk factors. The identification of environmental factors implication is crucial to understand the RA mechanism, and improves the diagnosis and the treatment of the disease.


Description:

The physiopathology of RA is multifactorial, implicating genetic and environmental factors. Within the environmental factors, the exact role of psychological stress and life events on the onset of the disease is still under question. In clinical practice, patients usually report the occurrence of a stressing life event before the diagnosis of the disease (mourning, dismissal, divorce…). Nevertheless, literature reviews present some discrepancies and did not lead to a clear identification of the role of psychological stress in RA onset. This is mainly due to the evaluation methods of stress within those previous studies, considering stress as a unique response of the organism without taking into account personal, sociological, biological or environmental history. The aim of the study is to analyze the impact of stress on the RA onset within an integrative model, to evaluate patient assessment of the stress, and to present strategies to fix it.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date July 4, 2019
Est. primary completion date July 4, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Patients RA :

Inclusion Criteria:

- patients aged over 18 years old

- patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years.

- Speaking and understanding French language

- Being informed about the study and having given his oral consent

Exclusion Criteria:

- Pregnant or breastfeeding women

- Patient who refuse to participate.

Control :

Inclusion Criteria:

- patients aged over 18 years old

- patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)

- Speaking and understanding French language

- Being informed about the study and having given his oral consent

Exclusion Criteria:

- Pregnant or breastfeeding women

- Patient who refuse to participate

Study Design


Intervention

Behavioral:
Questionnaire
Questionnaire
Biological:
blood sample
7 ml whole blood for Peripheral blood

Locations

Country Name City State
France CHU de Bordeaux - service de rhumatologie Bordeaux
France CH de Dax - service de rhumatologie Dax
France Hôpital Suburbain du Bouscat Le Bouscat
France CH de Libourne - service de rhumatologie Libourne
France CH de Pau - service de rhumatologie Pau

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Life events calculated over the year preceding the onset of PR symptoms Social Readjustment Rating Scale (SRRS) At inclusion (day 0)
Secondary Perceived stress Perceived Stress Scale (PSS) At inclusion (day 0)
Secondary Perceived control Multidimensional Health Locus of Control Scale (MHLCS) At inclusion (day 0)
Secondary Perceived social support Social Support Questionnaire (SSQ) At inclusion (day 0)
Secondary State Anxiety State-Trait Anxiety Inventory (STAI-Y-A) At inclusion (day 0)
Secondary Coping Ways of Coping Checklist Scale (WCC) At inclusion (day 0)
Secondary Cytokine levels in RA patients sera 12 months from baseline
Secondary Correlation between cytokine levels and RA activity 12 months from baseline
Secondary Correlation between cytokine levels and stress for RA patients 12 months from baseline
Secondary Identification of neuropathic pain for RA patients evalued by douleur-neuropathique 10 items questionnaire douleur-neuropathique 10 items questionnaire providing a score between 0 and 10, with a positive threshold value beyond 4/10. 12 months from baseline
Secondary Characterization of neuropathic pain for RA patients evalued by Neuropathic Pain Symptom Inventory questionnaire Neuropathic Pain Symptom Inventory questionnaire with 12 items to complete, providing for each item the presence (or the absence) of several pain symptoms 12 months from baseline
See also
  Status Clinical Trial Phase
Terminated NCT01682512 - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis Phase 3
Completed NCT00539760 - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers Phase 1
Active, not recruiting NCT03312465 - Anatomical Shoulder Domelock System Study
Completed NCT01208181 - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) Phase 3
Completed NCT03254810 - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects Phase 1
Completed NCT01711814 - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study Phase 2
Completed NCT03315494 - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers Phase 1
Withdrawn NCT03241446 - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA) Phase 1
Completed NCT02748785 - MTX Discontinuation and Vaccine Response Phase 4
Completed NCT02553018 - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe Phase 3
Active, not recruiting NCT02260778 - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce N/A
Completed NCT02569736 - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed NCT01750931 - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. Phase 2
Not yet recruiting NCT01154647 - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes N/A
Withdrawn NCT01204138 - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA Phase 2
Completed NCT00975130 - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Phase 3
Completed NCT00913458 - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Phase 4
Completed NCT00973479 - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy Phase 3
Completed NCT00550446 - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis Phase 2
Completed NCT00660647 - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Phase 3